Successful treatment of lymph node extramedullary plasmacytoma with bortezomib.
Pantelidou
D
D
Tsatalas
C
C
Margaritis
D
D
Anastasiadis
A G
AG
Kaloutsi
V
V
Argyropoulou
P
P
Prassopoulos
P
P
Bourikas
G
G
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D003131:Combined Modality Therapy / Q000379:methods; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007275:Injections, Intravenous; D008198:Lymph Nodes / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy*; D010954:Plasmacytoma / Q000000981:diagnostic imaging / Q000628:therapy*; D011719:Pyrazines / Q000008:administration & dosage*; D011879:Radiotherapy Dosage; D033581:Stem Cell Transplantation; D014057:Tomography, X-Ray Computed / Q000379:methods; D014182:Transplantation, Autologous
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D005047:Etoposide; D004317:Doxorubicin